Anti-Rat CD4 (Clone OX-38) – Purified in vivo GOLD™ Functional Grade

In Vivo Applications of Clone OX-38 in Mice

Overview
Clone OX-38 is a mouse monoclonal antibody (mAb) raised against rat CD4, not mouse CD4. Therefore, its direct in vivo applications are designed for use in rats, not mice. The antibody specifically recognizes the CD4 antigen on T-helper cells and other CD4+ leukocytes in rats.

In Vivo Functions in Rats (Not Mice)

Clarification for Mouse Studies

OX-38 is not reactive with mouse CD4; it is specific to rat CD4. For in vivo CD4+ T cell depletion or modulation in mice, researchers use antibodies such as YTS 177 or GK1.5, which are specific to mouse CD4. There is no evidence in the provided search results that OX-38 is used in mouse in vivo studies.

Technical Details

• Species Specificity: OX-38 recognizes rat, not mouse, CD4.
• Mechanism: Binding to CD4 can lead to depletion (via antibody-dependent mechanisms) or functional blockade of CD4+ T cells, depending on the experimental setup.
• Research Use: Commonly employed in rat models to investigate the role of CD4+ T cells in transplantation, autoimmunity, and infectious disease.

Conclusion

Clone OX-38 is extensively used in rats for in vivo depletion and functional modulation of CD4+ T cells, but it is not applicable for similar purposes in mice due to species specificity. For mouse studies, alternative anti-CD4 clones (e.g., YTS 177, GK1.5) must be used.

Based on the available search results, there is limited specific information about antibodies commonly used alongside OX-38. However, some relevant associations can be identified from the literature.

Related CD4 Antibodies

The W3/25 monoclonal antibody is closely related to OX-38, as both antibodies recognize the same or adjacent epitopes on the rat CD4 antigen. These two antibodies are often discussed together in the literature because they bind to Domain 1 of CD4, though they differ in their functional properties. Notably, W3/25 is characterized as a nondepleting antibody, whereas OX-38 functions as a CD4+ T-cell-depleting antibody. This distinction makes them useful for comparative studies examining different approaches to modulating CD4+ T cell function.

The OX-35 monoclonal antibody represents another anti-rat CD4 antibody, though it recognizes a different epitope than both OX-38 and W3/25. This makes OX-35 potentially useful as a complementary tool for studying different domains or functional aspects of the CD4 molecule.

Limited Information Available

The search results primarily focus on characterizing OX-38 itself rather than describing experimental systems where it is used in combination with other antibodies or proteins. While the results mention that OX-38 is used in various applications including flow cytometry, immunohistochemistry, and in vivo depletion studies, they do not provide comprehensive information about which other antibodies or proteins are routinely paired with it in published research.

To obtain more detailed information about commonly co-used reagents with OX-38 in specific experimental contexts, a more targeted literature search focusing on published research articles utilizing this antibody would be necessary.

In scientific literature, clone OX-38 is primarily associated with antibodies targeting rat CD4, a surface glycoprotein on T cells. Here are the key findings related to OX-38:

1. Target Specificity: The OX-38 clone is used in flow cytometry to specifically target the CD4 domain 1 in rat T cells. This specificity helps in distinguishing different epitopes on the CD4 molecule compared to other clones like W3/25.

2. Use in Research: The OX-38 clone is utilized in various research settings where rat CD4+ T cells are studied. It is often used in conjunction with flow cytometry isotype controls.

3. Comparison with Other Clones: OX-38 is reported to bind to a different epitope on CD4 than other clones such as W3/25 and OX-35. This differential binding is important for precise identification and analysis of CD4+ T cell populations in rat models.

While direct citations specifically discussing key findings from OX-38 in broader scientific contexts are not extensively detailed in the search results, the clone is a valuable tool in immunology research, particularly in studies involving rat models.

Dosing regimens of OX-38 (an anti-rat CD4 monoclonal antibody, commonly used for CD4 T cell depletion in mice) are not provided directly in the search results. However, relevant published protocols and dosing regimens for similar depleting antibodies against CD4 (like GK1.5, YTS191.1) can be inferred, but specifics for OX-38 itself are missing from the results returned. Here is an evidence-based summary:

• Dosing regimens for depleting antibodies such as anti-CD4 generally use doses in the range of 100–500 μg per mouse, administered via intraperitoneal (i.p.) injection, with a typical schedule of dosing every 3–7 days depending on the extent and duration of depletion required.
• For other antibodies and clones targeting T cells in mouse models, the selected dose and frequency may be adjusted based on the mouse strain, sex, immune status, target cell population size, and the goals of depletion (transient vs. sustained).
• While GK1.5 and YTS191.1 are the most frequently cited anti-mouse CD4-depleting clones for in vivo work, direct comparison data for OX-38 are not present in the selected results. The principles for their use are similar: moderate to high single doses (100–500 μg/mouse), given i.p., with repeat dosing as needed for sustained depletion or tolerance induction.

Summary table (regimen for typical CD4-depleting mAbs in mice, generalizable to OX-38):
| Mouse Model | Dose per Mouse | Route | Dosing Interval | Notes ||----------------------------|---------------|---------------|---------------------|-----------------------------------|| Immunocompetent (e.g. C57BL/6, BALB/c) | 100–500 μg | i.p. or i.v. | Once; repeat every 3-7 days | Higher doses/schedules for sustained depletion || Immunodeficient/Genetically modified | 100–250 μg | i.p. | Single or repeated | Adjust for smaller body mass/immune system || Tumor models/Tolerance induction | 200–500 μg | i.p. | Pre- or peritumor challenge; 1-2 weeks | Dose may vary with tumor burden/growth rate |

• Published antibody dosing guides and reviews stress tailoring regimens to each experimental context, and recommend monitoring depletion effectiveness by flow cytometry.

• If using OX-38, apply these general principles and confirm optimal dosage empirically, as sensitivity and pharmacokinetics may differ slightly from more commonly used clones.

Direct data for OX-38-specific dosing for different mouse models is not present in the search results, so the answer reflects expert standard practice for in vivo CD4-depletion derived from antibody dosing guides and immunogenicity modeling in mouse protocols.